Journal articles: 'Tall Stature'

1

Zargham, Shiva, and Jennifer Erin Crotty. "Tall Stature." Pediatrics in Review 35, no. 12 (December 2014): 538–39. http://dx.doi.org/10.1542/pir.35-12-538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zargham, Shiva, and Jennifer Erin Crotty. "Tall Stature." Pediatrics In Review 35, no. 12 (December 1, 2014): 538–39. http://dx.doi.org/10.1542/pir.35.12.538.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Harty, Jean R., Joseph G. Hollowell, and Karl G. Sieg. "Tall Stature." Clinical Pediatrics 32, no. 3 (March 1993): 179–80. http://dx.doi.org/10.1177/000992289303200313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Johnston, Derek I. "Tall stature." Current Paediatrics 2, no. 3 (September 1992): 137–39. http://dx.doi.org/10.1016/0957-5839(92)90252-m.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Butler, Gary E. "Assessing tall stature." Paediatrics and Child Health 29, no. 7 (July 2019): 293–96. http://dx.doi.org/10.1016/j.paed.2019.04.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bramswig, Jurgen H. "Short and Tall Stature." Annales Nestlé (English ed.) 65, no. 3 (2007): 117–27. http://dx.doi.org/10.1159/000112234.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Leung, Alexander K. C., Alexander A. C. Leung, and Kam Lun Hon. "Tall Stature in Children." Advances in Pediatrics 66 (August 2019): 161–76. http://dx.doi.org/10.1016/j.yapd.2019.04.004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Moon, Rebecca J., and Justin H. Davies. "Evaluation of tall stature." Paediatrics and Child Health 20, no. 1 (January 2010): 43–45. http://dx.doi.org/10.1016/j.paed.2009.09.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Lebedeva, Lidia S., Yulia A. Kucherova, and Elena Z. Godina. "Cartographic method for studying secular trend in male stature in Russia and neighboring countries in the 19-20th Centuries." Moscow University Anthropology Bulletin (Vestnik Moskovskogo Universiteta. Seria XXIII. Antropologia), no. 1 (June 23, 2022): 41–53. http://dx.doi.org/10.32521/2074-8132.2022.1.041-053.

Full text

Abstract:

Introduction. The article aims to study the regional differences in male stature during the 19-20th centuries in Russian Empire, USSR, Russia and some neighboring countries and to illustrate the observed changes in time using contemporary cartographic methods and the new source of information – the RLMS HSE dataset. We hypothesized that there are some areas with stable short and tall statures. Materials and methods. We used datasets with as large number of territorial units of the country as possible, published by D.N. Anuchin, V.V. Bunak, A.L. Purundzhan. To illustrate relevant datasets, the methodology of visualization was created. To make maps comparable with each other, especially, for the territory, like the European part of Russia, we made a surface interpolation. Results. We could suggest areas with more or less stable tall stature – near the Baltic Sea and Saint-Petersburg and between the contemporary cities of Kiev and Krasnodar. The area with stable short stature is situated in the middle part of Volga River – near Kazan city. Thus, the hypothesis was confirmed considering a new database. Moreover, according to the datasets, which illustrated the second part of the 20th century, the new area had appeared in Moscow and some neighboring territories. Secular changes in height for different regions and time periods were uneven, which may be connected with the different ethnic composition of the studied populations and various socioeconomic and demographic variables. Conclusion. Based on contemporary cartographic methods we illustrated the general pattern of changes in male stature, the idea of the consistency of the changes in male stature and the uneven changes in values across the territory. Some areas with stable short and tall statures first discovered by Anuchin are preserved till nowadays. Our research demonstrated the idea that areas could be formed under various circumstances. However, the overall trend has stayed the same over time despite the positive secular changes.

APA, Harvard, Vancouver, ISO, and other styles

10

BROOK, C. G. D., R. STANHOPE, M. A. PREECE, A. A. GREEN, and P. C. HINDMARSH. "Oestrogen treatment of tall stature." Archives of Disease in Childhood 79, no. 2 (August 1, 1998): 198. http://dx.doi.org/10.1136/adc.79.2.198c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Murray, Philip G., and Gary E. Butler. "How to assess tall stature." Paediatrics and Child Health 23, no. 9 (September 2013): 409–13. http://dx.doi.org/10.1016/j.paed.2013.05.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Kant, S. G., J. M. Wit, and M. H. Breuning. "Genetic Analysis of Tall Stature." Hormone Research in Paediatrics 64, no. 3 (2005): 149–56. http://dx.doi.org/10.1159/000088589.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Corredor, Beatriz, Mehul Dattani, Chiara Gertosio, and Mauro Bozzola. "Tall Stature: A Challenge for Clinicians." Current Pediatric Reviews 15, no. 1 (April 5, 2019): 10–21. http://dx.doi.org/10.2174/1573396314666181105092917.

Full text

Abstract:

Clinicians generally use the term “tall stature” to define a height more than two standard deviations above the mean for age and sex. In most cases, these subjects present with familial tall stature or a constitutional advance of growth which is diagnosed by excluding the other conditions associated with overgrowth. Nevertheless, it is necessary to be able to identify situations in which tall stature or an accelerated growth rate indicate an underlying disorder. A careful physical evaluation allows the classification of tall patients into two groups: those with a normal appearance and those with an abnormal appearance including disproportion or dysmorphism. In the first case, the growth rate has to be evaluated and, if it is normal for age and sex, the subjects may be considered as having familial tall stature or constitutional advance of growth or they may be obese, while if the growth rate is increased, pubertal status and thyroid function should be evaluated. In turn, tall subjects having an abnormal appearance can be divided into proportionate and disproportionate syndromic patients. Before initiating further investigations, the clinician needs to perform both a careful physical examination and growth evaluation. To exclude pathological conditions, the cause of tall stature needs to be considered, although most children are healthy and generally do not require treatment to inhibit growth progression. In particular cases, familial tall stature subject can be treated by inducing puberty early and leading to a complete fusion of the epiphyses, so final height is reached. This review aims to provide proposals about the management of tall children.

APA, Harvard, Vancouver, ISO, and other styles

14

Willegger, Madeleine, Markus Schreiner, Alexander Kolb, Reinhard Windhager, and Catharina Chiari. "Epiphysiodesis for the treatment of tall stature and leg length discrepancy." Wiener Medizinische Wochenschrift 171, no. 5-6 (March 18, 2021): 133–41. http://dx.doi.org/10.1007/s10354-021-00828-8.

Full text

Abstract:

SummaryPainful orthopedic conditions associated with extreme tall stature and leg length discrepancy (LLD) include back pain and adopting bad posture. After failure of conservative treatment options, blocking of the growth plates (epiphysiodesis) around the knee emerged as gold standard in patients with tall stature and LLD in the growing skeleton. Surgical planning includes growth prediction and evaluation of bone age. Since growth prediction is associated with a certain potential error, adequate planning and timing of epiphysiodesis are the key for success of the treatment. LLD corrections up to 5 cm can be achieved, and predicted extreme tall stature can be limited. Percutaneous epiphysiodesis techniques are minimally invasive, safe and efficient methods with low complication rates. In general, a multidisciplinary approach should be pursued when treating children and adolescents with tall stature.

APA, Harvard, Vancouver, ISO, and other styles

15

Albuquerque, Edoarda V. A., Renata C. Scalco, and Alexander A. L. Jorge. "MANAGEMENT OF ENDOCRINE DISEASE: Diagnostic and therapeutic approach of tall stature." European Journal of Endocrinology 176, no. 6 (June 2017): R339—R353. http://dx.doi.org/10.1530/eje-16-1054.

Full text

Abstract:

Tall stature is defined as a height of more than 2 standard deviations (s.d.) above average for same sex and age. Tall individuals are usually referred to endocrinologists so that hormonal disorders leading to abnormal growth are excluded. However, the majority of these patients have familial tall stature or constitutional advance of growth (generally associated with obesity), both of which are diagnoses of exclusion. It is necessary to have familiarity with a large number of rarer overgrowth syndromes, especially because some of them may have severe complications such as aortic aneurysm, thromboembolism and tumor predisposition and demand-specific follow-up approaches. Additionally, endocrine disorders associated with tall stature have specific treatments and for this reason their recognition is mandatory. With this review, we intend to provide an up-to-date summary of the genetic conditions associated with overgrowth to emphasize a practical diagnostic approach of patients with tall stature and to discuss the limitations of current growth interruption treatment options.

APA, Harvard, Vancouver, ISO, and other styles

16

Alpert, B. S. "Consultation with the Specialist: Tall Stature." Pediatrics in Review 19, no. 9 (September 1, 1998): 303–5. http://dx.doi.org/10.1542/pir.19-9-303.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Davies, J. H., and T. Cheetham. "Investigation and management of tall stature." Archives of Disease in Childhood 99, no. 8 (May 15, 2014): 772–77. http://dx.doi.org/10.1136/archdischild-2013-304830.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Elias, Lucila L. K., Angela Huebner, Louise A. Metherell, Atilio Canas, Gary L. Warne, Maria L. Manca Bitti, Stefano Cianfarani, Peter E. Clayton, Martin O. Savage, and Adrian J. L. Clark. "Tall stature in familial glucocorticoid deficiency." Clinical Endocrinology 53, no. 4 (October 2000): 423–30. http://dx.doi.org/10.1046/j.1365-2265.2000.01122.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Sotos, Juan F., and Jesús Argente. "Overgrowth Disorders Associated with Tall Stature." Advances in Pediatrics 55, no. 1 (September 2008): 213–54. http://dx.doi.org/10.1016/j.yapd.2008.07.019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Lesser, Larry. "The Stature of Salary: Raised Expectations or a Tall Tale?" Mathematics Teacher 110, no. 3 (October 2016): 168–69. http://dx.doi.org/10.5951/mathteacher.110.3.0168.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Aslan, Nagehan. "A rare cause of tall stature: Sotos syndrome." Dicle Medical Journal 41, no. 4 (December 1, 2014): 760–62. http://dx.doi.org/10.5798/diclemedj.0921.2014.04.0516.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Adamovičová, Kateřina, Lukáš Plachý, Jan Lebl, Stanislava Koloušková, and Štěpánka Průhová. "Current perspectives on the aetiology of tall stature in children and adolescents (2): Non-syndromic tall stature." Česko-slovenská pediatrie 77, Suppl.3 (November 4, 2022): S18—S23. http://dx.doi.org/10.55095/cspediatrie2022/054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Hwaung, Phoenix, Moonseong Heo, Brianna Bourgeois, Samantha Kennedy, John Shepherd, and Steven B. Heymsfield. "Greater Height Is Associated with a Larger Carotid Lumen Diameter." Medicines 6, no. 2 (May 14, 2019): 57. http://dx.doi.org/10.3390/medicines6020057.

Full text

Abstract:

Background: Previous studies link tall stature with a reduced ischemic stroke risk. One theory posits that tall people have larger cerebral artery lumens and therefore have a lower plaque occlusion risk than those who are short. Previous studies have not critically evaluated the associations between height and cerebral artery structure independent of confounding factors. Methods: The hypothesis linking stature with cerebral artery lumen size was tested in 231 adults by measuring the associations between height and common carotid artery diameter (CCAD) and intima–media thickness (IMT) after controlling for recognized vascular influencing factors (e.g., adiposity, blood pressure, plasma lipids, etc.). Results: Height remained a significant CCAD predictor across all developed multiple regression models. These models predict a ~0.03 mm increase in CCAD for each 1-cm increase in height in this sample. This magnitude of CCAD increase with height represents over a 60% enlargement of the artery’s lumen area across adults varying in stature from short (150 cm) to tall (200 cm). By contrast, IMT was non-significantly correlated with height across all developed regression models. Conclusions: People who are tall have a larger absolute CCAD than people who are short, while IMT is independent of stature. These observations potentially add to the growing cardiovascular literature aimed at explaining the lower risk of ischemic strokes in tall people.

APA, Harvard, Vancouver, ISO, and other styles

24

Vasco de Albuquerque Albuquerque, Edoarda, Mariana Ferreira de Assis Funari, Elisângela Pereira de Souza Quedas, Rachel Sayuri Honjo Kawahira, Raquel Soares Jallad, Thaís Kataoka Homma, Regina Matsunaga Martin, et al. "Genetic investigation of patients with tall stature." European Journal of Endocrinology 182, no. 2 (February 2020): 139–47. http://dx.doi.org/10.1530/eje-19-0785.

Full text

Abstract:

Context Patients with tall stature often remain undiagnosed after clinical investigation and few studies have genetically assessed this group, most of them without a systematic approach. Objective To assess prospectively a group of individuals with tall stature, with and without syndromic features, and to establish a molecular diagnosis for their growth disorder. Design Screening by karyotype (n = 42), chromosome microarray analyses (CMA) (n = 16), MS-MLPA (n = 2) targeted panel (n = 12) and whole-exome sequencing (n = 31). Patients and methods We selected 42 patients with tall stature after exclusion of pathologies in GH/IGF1 axis and divided them into syndromic (n = 30) and non-syndromic (n = 12) subgroups. Main outcome measures Frequencies of pathogenic findings. Results We identified two patients with chromosomal abnormalities including SHOX trisomy by karyotype, one 9q22.3 microdeletion syndrome by CMA, two cases of Beckwith–Wiedemann syndrome by targeted MS-MLPA analysis and nine cases with heterozygous pathogenic or likely pathogenic genetic variants by multigene analysis techniques (FBN1 = 3, NSD1 = 2, NFIX = 1, SUZ12 = 1, CHD8 = 1, MC4R = 1). Three of 20 patients analyzed by WES had their diagnosis established. Only one non-syndromic patient had a definitive diagnosis. The sequential genetic assessment diagnosed 14 out of 42 (33.3%) tall patients. Conclusion A systematic molecular approach of patients with tall stature was able to identify the etiology in 13 out of 30 (43.3%) syndromic and 1 out of 12 (8.3%) non-syndromic patients, contributing to the genetic counseling and avoiding unfavorable outcomes in the syndromic subgroup.

APA, Harvard, Vancouver, ISO, and other styles

25

Drop, S. L. S. "Sex Steroid Treatment of Constitutionally Tall Stature." Endocrine Reviews 19, no. 5 (October 1, 1998): 540–58. http://dx.doi.org/10.1210/er.19.5.540.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Drop, Stenvert L. S., Wouter J. de Waal, and Sabine M. P. F. de Muinck Keizer-Schrama. "Sex Steroid Treatment of Constitutionally Tall Stature*." Endocrine Reviews 19, no. 5 (October 1, 1998): 540–58. http://dx.doi.org/10.1210/edrv.19.5.0345.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Karuppiah, Dharshini, and Mithusha Markandu. "Tall stature due to Beckwith Wiedemann Syndrome." Sri Lanka Journal of Diabetes Endocrinology and Metabolism 8, no. 2 (August 29, 2018): 43. http://dx.doi.org/10.4038/sjdem.v8i2.7364.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Hlndmarsh, Peter. "Oestrogen therapy for girls with tall stature." Clinical Endocrinology 37, no. 3 (September 1992): 199–200. http://dx.doi.org/10.1111/j.1365-2265.1992.tb02309.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Hannema, Sabine E., and Lars Sävendahl. "The Evaluation and Management of Tall Stature." Hormone Research in Paediatrics 85, no. 5 (2016): 347–52. http://dx.doi.org/10.1159/000443685.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Alexander, Saji Daniel, and Peter Hindmarsh. "The evaluation and management of tall stature." Current Paediatrics 14, no. 5 (October 2004): 414–21. http://dx.doi.org/10.1016/j.cupe.2004.05.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Adamovičová, Kateřina, Lukáš Plachý, Jan Lebl, Stanislava Koloušková, and Štěpánka Průhová. "Current perspectives on the aetiology of tall stature in children and adolescents (1): Syndromes associated with tall stature." Česko-slovenská pediatrie 77, Suppl.3 (November 4, 2022): S11—S17. http://dx.doi.org/10.55095/cspediatrie2022/053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Weyand, Peter G., Bethany R. Smith, Nicole S. Schultz, Lindsay W. Ludlow, Maurice R. Puyau, and Nancy F. Butte. "Predicting metabolic rate across walking speed: one fit for all body sizes?" Journal of Applied Physiology 115, no. 9 (November 1, 2013): 1332–42. http://dx.doi.org/10.1152/japplphysiol.01333.2012.

Full text

Abstract:

We formulated a “one-size-fits-all” model that predicts the energy requirements of level human walking from height, weight, and walking speed. Our three-component model theorizes that the energy expended per kilogram per stride is independent of stature at mechanically equivalent walking speeds. We measured steady-state rates of oxygen uptake of 78 subjects who spanned a nearly twofold range of statures (1.07–2.11 m) and sevenfold range of body masses (16–112 kg) at treadmill speeds from 0.4 to 1.9 m/s. We tested the size independence of the model by deriving best-fit equations in the form of the model on four stature groups ( n ≥ 15): short, moderately short, moderately tall, and tall. The mean walking metabolic rates predicted by these four independently derived equations for the same set of reference subjects ( n = 16; stature range: 1.30–1.90 m) agreed with one another to within an average of 5.2 ± 3.7% at the four intermediate speeds in our protocol. We next evaluated the model's gross predictive accuracy by dividing our 78 subjects into 39 stature-matched pairs of experimental and validation group subjects. The model best-fit equation derived on the experimental group subjects predicted the walking metabolic rates of the validation group subjects to within an average of 8.1 ± 6.7% ( R2 = 0.90; standard error of estimate = 1.34 ml O2·kg−1·min−1). The predictive error of the American College of Sports Medicine equation (18.0 ± 13.1%), which does not include stature as a predictor, was more than twice as large for the same subject group. We conclude that the energy cost of level human walking can be accurately predicted from height, weight, and walking speed.

APA, Harvard, Vancouver, ISO, and other styles

33

Siddiqi, Ahmed, Jared A. Warren, Michael Groover, Daniel Santana, Hiba K. Anis, Atul F. Kamath, Robert M. Molloy, Carlos A. Higuera, and Nicolas S. Piuzzi. "Tall-Statured Patients Have Similar Outcomes to Normal Height Patients after Primary Total Hip Arthroplasty." Journal of Hip Surgery 04, no. 02 (June 2020): 060–65. http://dx.doi.org/10.1055/s-0040-1712519.

Full text

Abstract:

AbstractTotal hip arthroplasty (THA) has been proven to be a safe and efficacious operation; however, there is a paucity of literature on outcomes in patients in the 99th percentile for height. The objectives of this study were to identify differences in (1) implant selection, (2) operative times, (3) intraoperative and postoperative complications, (4) 90-day readmission, (5) all cause reoperation rates, and (6) hospital length of stay (LOS), in tall-statured patients compared with a matched control cohort. An electronic research request was used to identify 12,850 patients who underwent THA from January 2012 to December 2016 with minimum 1-year follow-up at a single health care system for retrospective chart review. Patients were identified in the 99th percentile for height (193 cm for males and 177 cm for females) and then matched to controls based on gender, race, age, body mass index, and Charlson comorbidity index. A total of 260 THA patients (2%) were identified in the 99th percentile for height. The tall-statured patients were then matched to 248 patients of normal stature. The exclusion criteria was met by 172 tall-statured patients and 165 normal-statured patients. Final analysis comprised of 86 tall-statured patients (100 THA) and 83 matched normal-statured patients (92 THA). Baseline demographics information and the outcomes of interest were then compared. The mean height of the female patients in the tall cohort was 181.01 ± 2.51 cm compared with 166.6 ± 6.98 cm for the control group (p < 0.001), while it was 195.25 ± 4.03 cm for male patients in the tall cohort and 174.11 ± 4.63 cm for the control cohort (p < 0.001). Tall-statured patients had larger acetabular cups (p < 0.001) and femoral head (p = 0.046) components. There were no differences in reoperation (p = 0.282), 90-day readmissions (p = 0.862), intraoperative fractures (p = 0.228), postoperative complications (p = 0.678), operative times (p = 0.890), and LOS (p = 0.099) between the tall-statured and normal-statured patients. Patients that are in the 99th percentile for height have similar outcomes to patients that are of normal height. The level of evidence of this study is level 3.

APA, Harvard, Vancouver, ISO, and other styles

34

Hiroi, Naoki, Takamasa Ichijo, Yasuyo Tsuchida, and Gen Yoshino. "Turner Syndrome With Gonadal Dysgenesis and Tall Stature." Endocrinologist 17, no. 3 (May 2007): 172–74. http://dx.doi.org/10.1097/ten.0b013e31806b9522.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Baron, Jeffrey, Lars Sävendahl, Francesco De Luca, Andrew Dauber, Moshe Phillip, Jan M. Wit, and Ola Nilsson. "Short and tall stature: a new paradigm emerges." Nature Reviews Endocrinology 11, no. 12 (October 6, 2015): 735–46. http://dx.doi.org/10.1038/nrendo.2015.165.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Edouard, Thomas. "What treatment for a child with tall stature?" Annales d'Endocrinologie 78, no. 2 (June 2017): 104–5. http://dx.doi.org/10.1016/j.ando.2017.04.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

HINDMARSH, P. C., R. STANHOPE, B. E. KENDALL, and C. G. D. BROOK. "TALL STATURE: A CLINICAL, ENDOCRINOLOGICAL AND RADIOLOGICAL STUDY." Clinical Endocrinology 25, no. 3 (September 1986): 223–31. http://dx.doi.org/10.1111/j.1365-2265.1986.tb01686.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Werder, E. A., P. Waibel, D. Sege, and R. Flury. "Severe thrombosis during oestrogen treatment for tall stature." European Journal of Pediatrics 149, no. 6 (March 1990): 389–90. http://dx.doi.org/10.1007/bf02009654.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Liu, Fan, A. Emile J. Hendriks, Arwin Ralf, Annemieke M. Boot, Emelie Benyi, Lars Sävendahl, Ben A. Oostra, et al. "Common DNA variants predict tall stature in Europeans." Human Genetics 133, no. 5 (November 20, 2013): 587–97. http://dx.doi.org/10.1007/s00439-013-1394-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Noordam, C., S. van Daalen, and BJ Otten. "Treatment of tall stature in boys with somatostatin analogue 201–995: effect on final height." European Journal of Endocrinology 154, no. 2 (February 2006): 253–57. http://dx.doi.org/10.1530/eje.1.02087.

Full text

Abstract:

Background: An optimal treatment for tall stature in boys in terms of efficacy and safety is not available. Treatment with somatostatin analogue 201–995 (SMS) has been tried with positive short-term results. Methods: We evaluated the effect of SMS treatment on reducing adult height. Over 2 years, 16 boys presenting to our university hospital with tall stature (constitutional tall stature (n = 13), Marfan syndrome (n = 2) and tethered spinal cord (n = 1)) with a predicted final height above 197 cm were included in the study and prospectively followed until final height was reached. As one boy was lost to follow-up we have reported on 15 boys. Treatment with SMS as a single subcutaneous dose was started and continued until final height was reached. In eight boys androgens were given to induce puberty after the start of SMS and five boys were on treatment with androgens prior to SMS treatment. Effect on reduction of final height prediction, calculated with the index of potential height based on the bone age of Greulich and Pyle, was the main outcome measure. Standard anthropometric assessments were performed a year before and every 3 months during treatment. Bone age was assessed by the method of Greulich and Pyle at the start and after 6 and 12 months. Results: Mean reduction in final height prediction (predicted adult height minus achieved adult height) was −0.1 cm (range −6.4 to +5.7). In three boys, asymptomatic microlithiasis of the gall bladder was diagnosed. Conclusions: We have concluded that, in spite of encouraging short-term results, long-term treatment with SMS does not reduce final height in a manner sufficient to justify SMS treatment in tall stature.

APA, Harvard, Vancouver, ISO, and other styles

41

Bosy-Westphal, Anja, Sandra Plachta-Danielzik, Ralf-Peter Dörhöfer, and Manfred J. Müller. "Short stature and obesity: positive association in adults but inverse association in children and adolescents." British Journal of Nutrition 102, no. 3 (March 2, 2009): 453–61. http://dx.doi.org/10.1017/s0007114508190304.

Full text

Abstract:

Shorter than average adults are at a higher risk for obesity and are also more susceptible to diabetes and CVD, independent of BMI. In contrast, taller children have a higher risk of obesity. We hypothesised that short stature is related to adverse body composition and that the association between stature and obesity differs between generations. In a cross-sectional German database of 213 804 adults and 12 411 children and adolescents, the prevalence of overweight and obesity was compared between percentiles of height. The association between stature and percentage of fat mass (%FM), lean BMI (LBMI; kg/m2) or waist:hip ratio (in children only) was analysed within BMI groups. In adults, the prevalence of BMI >30 kg/m2 gradually increased with decreasing percentile of height whereas in children and adolescents, a positive association between height and weight status was observed. Short-stature women and girls had a 0·8–3·2 % lower %FM than tall subjects (P < 0·05), whereas no trend for %FM was observed in males. When compared with tall subjects, LBMI was 0·2–0·6 kg/m2 lower in short-stature men, as well as obese women (P < 0·05). There was a non-significant trend for a lower LBMI and a higher waist:hip ratio in shorter children. In conclusion, short stature is associated with an increased risk of obesity in adults. Cardiometabolic risk in short stature is not explained by an adverse body composition.

APA, Harvard, Vancouver, ISO, and other styles

42

Hansche, Paul E. "Two Genes that Induce Brachytic Dwarfism in Peach." HortScience 23, no. 3 (June 1988): 604–6. http://dx.doi.org/10.21273/hortsci.23.3.604.

Full text

Abstract:

Abstract Crosses between brachytic dwarf (dwf) and standard (tall) trees in the peach breeding stock of the Univ. of California at Davis revealed two recessive genes with distinguishable effects on stature. It was concluded that one of these is the Dw/dw gene postulated by Lammerts. This gene was introduced to the United States through PI 41395, ‘Swatow’, in 1915. In homozygotes it effects a reduction in the internode length over that of standard trees from 18 ± 3.1 mm to 7.7 ± 2 mm, which results in 6-year-old trees averaging 1.37 ± 0.25 m in stature at Davis, Calif. The recessive allele, dw2, of the other gene, Dw2/dw2, is hypostatic to the Dw allele of the Dw/dw gene. It was found to be present, but not expressed, in the standard (tall cultivars Kearney, Red Cal, and Fire Red). Doubly recessive homozygotes (of genotype dw/dw, dw/2dw2) have an internode distance of 4.4 ± 0.8 mm and a stature, at 6 years, of 0.92 ± 0.18 m.

APA, Harvard, Vancouver, ISO, and other styles

43

Hasan, M. J., Umma Kulsum, M. H. Rahman, M. Nur-E-Elahi, and A. K. M. Shamsuddin. "GENETIC DIVERSITY IN RESTORER LINES OF HYBRID RICE (Oryza sativa L.)." Bangladesh Journal of Plant Breeding and Genetics 25, no. 2 (December 30, 2012): 09–14. http://dx.doi.org/10.3329/bjpbg.v25i2.18662.

Full text

Abstract:

An experiment was conducted with 30 restorer lines to identify most diverse lines in respect of morphological traits for developing heterotic rice hybrids. Thirty restorer lines were classified into four distinct clusters based on mean values of different morphological traits and days to maturity. Again these restorer lines were partitioned into very early, early, medium and late maturing groups. Only one line in very early maturing group had tall plant stature with maximum thousand grain weight but less in yield potential. Early maturing group contained 8 lines from different clusters having short plant stature with short flag leaf and moderate yielding ability. Medium maturing group included 13 lines characterized by medium plant stature with high tillering, excellent spikelet fertility, high grains per panicle and very good yielding ability. Late maturing group contained 8 lines featured by tall plant stature with excellent yield and yield contributing characters. Late maturing restorers BR827R, BR168R and BR736R had maximum genetic distance from centroid indicating extent of heterosis and very high yielding ability. Combining ability and heterosis study with short duration CMS lines may be fruitful for the development of desired hybrid.DOI: http://dx.doi.org/10.3329/bjpbg.v25i2.18662

APA, Harvard, Vancouver, ISO, and other styles

44

Maqsood, Hira. "Disparity in Populace Phenotype Impels Predisposition to Variations in Health Status." Pakistan Journal of Public Health 11, no. 3 (October 25, 2021): 136–42. http://dx.doi.org/10.32413/pjph.v11i3.602.

Full text

Abstract:

Background: The disparity in populace phenotype, embracing stature and pigmentation, drives of internal physiological constituent and adaptation to the external environment, impel variations in populace health status. The study tends to explore how significantly populaces phenotype influenced by internal or external exposures, and how effectually it prognosticates predisposition to variant health states. Methods: Ecological study encompassing twenty states residing on antipodes (North and South) endures distinct exposures, exhibit disparate phenotypes, execute different health status. Each State selected employing non-proportion quota sampling, standing extreme on either stature or pigmentation, residing in cold or hot region, contrasted on considered variables embracing UV-index, malnutrition, healthy life expectancy, fertility rate, natural increase, and top five causes of mortality. All computation, analysis, and interpretation perform employing MS-EXCEL. The complete compilation phase last from March to June 2019. Results: Findings reveal a strong association between exposures and phenotypes, UV-index and pigmentation (r = 0.96), malnutrition and stature (r = -0.81). Stature descends and pigmentation ascends along the latitude (North to South). Populace light pigmentation tall stature executes healthy prolong life span contrast to deep pigmentation standing short. Cardiac and cancer diseases significantly reported among statured nations. While high susceptibility to Influenza/ Pneumonia, and HIV/AIDS observe in pigmented nations. Conclusion: Decisively homo sapiens phenotypes inordinately servile to internal and external exposures effectually prognosticate predisposition to distinct health states. Enforcement of measures mitigating populace internal and external exposure can elicit desire output in phenotype and outcomes in health status.

APA, Harvard, Vancouver, ISO, and other styles

45

Weimann, Edda, and Christoph Brack. "Severe Thrombosis during Treatment with Ethinylestradiol for Tall Stature." Hormone Research 45, no. 6 (1996): 261–63. http://dx.doi.org/10.1159/000184801.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Dickerman, Z., M. Kalijman, R. Keret, A. Silbergeld, B. Bauman, A. Zacharia, Z. Zadik, and Z. Laron. "24-HOUR GH SECRETION PATTERN IN FAMILIAL TALL STATURE." Pediatric Research 20, no. 11 (November 1986): 1196. http://dx.doi.org/10.1203/00006450-198611000-00135.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Malina, Robert M. "Attained Size and Growth Rate of Female Volleyball Players between 9 and 13 Years of Age." Pediatric Exercise Science 6, no. 3 (August 1994): 257–66. http://dx.doi.org/10.1123/pes.6.3.257.

Full text

Abstract:

The growth status and rate of a mixed-longitudinal sample (N = 19) of female volleyball players 9–13 years of age were compared to reference data for the general population. The athletes were measured at the beginning and end of the school year. Growth rates in stature and weight adjusted to 6-month intervals were calculated. The results indicate mean statures that are above U.S. reference medians and mean weights that are near the medians (i.e., tall girls with average body weights). Estimated half-year growth rates in stature and weight from 10.0–13.0 years closely match the respective medians of the Fels longitudinal study. The data thus suggest that the larger body size of young volleyball players is not a function of accelerated growth rate during these early adolescent ages and, thus, not due to earlier maturation; body size is likely genotypic and probably reflects selection at relatively young ages for the size demands of the sport.

APA, Harvard, Vancouver, ISO, and other styles

48

Huddart, Richard, and Daphne Chapleo. "Denis Frank Oliver." Veterinary Record 183, no. 3 (July 19, 2018): 74. http://dx.doi.org/10.1136/vr.k3181.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Carvalho, Luciani R., Anna Flãvia Benedetti, and Julia Oliveira. "RF17 | PMON24 The paradox of combined pituitary hormone deficiency and tall stature: a glimpse from exome sequencing." Journal of the Endocrine Society 6, Supplement_1 (November 1, 2022): A463. http://dx.doi.org/10.1210/jendso/bvac150.963.

Full text

Abstract:

Abstract Introduction An intact GH-IGF-1 axis is known to be essential for proper growth. However, cases in which individuals with growth hormone deficiency (GHD) reach target height without the use of GH suggest that other mechanisms may play a role in the growth process. Out of 209 patients with hypopituitarism followed in the endocrinology clinic at HCFMUSP, 9 presented with normal stature despite GHD and hypogonadotropic hypogonadism. Among them, 1 male patient presented with tall stature. The mechanisms under growth without growth hormone are poorly understood, so we hypothesized that genetic mutations in genes related to tall stature could be a plausible explanation. The aim of the present work was to look for allelic variants in the exome that could be associated with tall stature, combined pituitary hormone deficiency and/or skeletal deformities. The index male patient presented at the age of 28 to a medical assistance due to the lack of pubertal development, leading to the diagnosis of FSH/LH and TSH deficiencies and thus treated accordingly. He was still growing even under testosterone replacement and noticed that his hand and fingers also got bigger in this period. At 32-year-old he presented to our service with a stature of 193.5cm (z score of +2.40) being out of his target height range. An arm span of 195cm was notice together with skeletal deformities such as claw toes, trigger fingers in hands and a barrel chest. At this time ACTH and GH deficiencies were diagnosed and an adult dose of GH was initiated. Over one year treatment he grew 1 cm even presenting complete closed epiphyses in hands but incomplete epiphyseal fusion in the iliac crest (Risser 4). In the skeletal X ray scoliosis, deformities in hands and feet were noticed. Pituitary MRI revealed an ectopic neurohypophysis and a reduced adenohypophysis. Whole exome sequencing was performed and allelic variants in exonic or splice site regions with frequency of less than 1% were prioritized. Out of 26 variants, 13 were classified as VUS or pathogenic in the genes PSG4, ZGPAT, LRP2, LRP5, LRP6, RYR1, REL SPAST, SDHC, EGFR, ARID3B and TGFB2, being the last 5 genes never described in 4 different populational databases (gnomAD, 1000G, ABraOM and SELAdb). Allelic variant in TGFB2 gene has been related to Marfan syndrome. Family members are having these genes in the process of being segregated. Conclusion Mutations in genes related to tall stature may be a mechanism that could explains normal growth among individuals with GHD. Presentation: Sunday, June 12, 2022 12:42 p.m. - 12:47 p.m., Monday, June 13, 2022 12:30 p.m. - 2:30 p.m.

APA, Harvard, Vancouver, ISO, and other styles

50

Hindmarsh, P. C., P. J. Pringle, and C. G. D. Brook. "The 24-hour growth hormone secretion in a boy with giantism." Acta Endocrinologica 117, no. 3 (March 1988): 403–8. http://dx.doi.org/10.1530/acta.0.1170403.

Full text

Abstract:

Abstract. The endocrinological and radiological findings in a 7.5-year-old boy with giantism are reported and compared with an age and sex matched normal tall boy. A 24-h GH profile demonstrated a persistently elevated GH concentration (mean GH concentration: giant 19.3 mU/l; tall boy 5.4 mU/l) with loss of the dominant GH periodicity of 3 h seen in the boy with tall stature and substitution with one of 8 h. These data support the view that giantism and acromegaly are similar diseases occurring prior to and following epiphyseal fusion, respectively.

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Tall Stature'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles